To meet the growing needs to examine much larger tissue samples, researchers at the University of Strathclyde in Glasgow, Scotland has developed the 70cm mesolens, with its 8cm diameter, the only device in the world which will be able to capture details in organisms which are too big to be examined, in just a second to improve the development of new drugs.
As a part of the President’s fiscal year (FY) 2013 budget the U.S. Food and Drug Administration has asked a budget of $4.5 billion on medical product development, protect patients and ensure safety of the food supply to support public health.
A study recently has proved that stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack. The cells, called cardiosphere-derived stem cells, regrew damaged heart muscles and reversed scarring one year later, the authors say.
USA-based Medivation (NASDAQ: MDVN) and global drugs behemoth Pfizer (NYSE: PFE) have finally decided to discontinue the development of Dimebon also known as latrepirdine, for all indications and will terminate the ongoing open label extension study in Alzheimer’s disease.
India’s health ministry is planning to amend 72-year-old Drugs and Cosmetics Act in order to recognize medical devices as a separate category. There are currently only 14 medical devices regulated by the Drug Controller General of India (DCGI). Amending the Drugs and Cosmetics Act would bring all medical devices under regulation in India.
Leading Pharma industry experts plan to be at the Pharma Market Research Conference which takes place on February 7-8 at the Hilton Parsippany Hotel in New Jersey.
Date: 21 Feb 2012 – 23 Feb 2012
Place: Florence, Italy
Organized by: ECDC,Istituto Superiore di Sanita’ (ISS)
and Agenzia Sanitaria Locale (ASL)
Epidemiological methods applied to vaccine preventable diseases is a 3 day workshop which will focus on building the capacity to organize, manage, and conduct training on epidemiological methods applied to vaccine-preventable diseases (VPD). The goal is to improve the participants’ skills as trainers.
Recently U.S. Food and Drug Administration has approved INLYTA(R) axitinib, a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) who have not responded to another drug for this type of cancer.
Programs for biosimilar drugs usually need at least one preclinical study to support the clinical phase of development. This study must have pharmacokinetic, immunogenicity and toxicological components and provide insight into the similarities and differences (i.e., comparability) between the biosimilar and the innovator drug.